RESEARCH

Vaspin promotes insulin sensitivity in elderly muscle and is upregulated in obesity

Thomas Nicholson¹, Chris Church², Kostas Tsintzas³, Robert Jones³, Leigh Breen¹, Edward T Davis⁴, David J Baker² and Simon W Jones¹

¹Institute of Inflammation and Ageing, MRC-ARUK Centre for Musculoskeletal Ageing Research, University of Birmingham, Birmingham, UK

²MedImmune, Cardiovascular and Metabolic Disease (CVMD), Milstein Building, Cambridge, UK

³MRC-ARUK Centre for Musculoskeletal Ageing Research, School of Life Sciences, Faculty of Medicine & Health Sciences, University of Nottingham, Nottingham, UK

⁴The Royal Orthopaedic Hospital NHS Foundation Trust, Northfield, Birmingham, UK

Correspondence should be addressed to S W Jones: S.W.Jones@bham.ac.uk

Abstract

Adipokines have emerged as central mediators of insulin sensitivity and metabolism, in part due to the known association of obesity with metabolic syndrome disorders such as type 2 diabetes. Recent studies in rodents have identified the novel adipokine vaspin as playing a protective role in inflammatory metabolic diseases by functioning as a promoter of insulin sensitivity during metabolic stress. However, at present the skeletal muscle and adipose tissue expression of vaspin in humans is poorly characterised. Furthermore, the functional role of vaspin in skeletal muscle insulin sensitivity has not been studied. Since skeletal muscle is the major tissue for insulin-stimulated glucose uptake, understanding the functional role of vaspin in human muscle insulin signalling is critical in determining its role in glucose homeostasis. The objective of this study was to profile the skeletal muscle and subcutaneous adipose tissue expression of vaspin in humans of varying adiposity, and to determine the functional role of vaspin in mediating insulin signalling and glucose uptake in human skeletal muscle. Our data shows that vaspin is secreted from both human subcutaneous adipose tissue and skeletal muscle, and is more highly expressed in obese older individuals compared to lean older individuals. Furthermore, we demonstrate that vaspin induces activation of the PI3K/AKT axis, independent of insulin receptor activation, promotes *GLUT4* expression and translocation and sensitises older obese human skeletal muscle to insulin-mediated glucose uptake.

Key Words

- ▶ skeletal muscle
- ▶ adipokines
- ▶ insulin
- ▶ obesity
- ▶ myotubes
- ▶ adipose tissue

Journal of Endocrinology
(2019) **241**, 31–43

Introduction

The recognition that adipose tissue is an endocrine organ, capable of secreting a plethora of adipose-secreted cytokines (adipokines) that mediate tissue crosstalk, has transformed our understanding of metabolism, with implications for the treatment of metabolic diseases such as type 2 diabetes (Bluher 2014, Bluher & Mantzoros 2015). It has long been established that the accumulation of

abdominal fat (central adiposity) is associated with insulin resistance (Pratley *et al.* 1995, Carey *et al.* 1996, Kahn & Flier 2000) and it is now known that in obese individuals the adipose tissue becomes inflamed, with infiltrated T lymphocytes (Zeyda *et al.* 2011) and macrophages (Weisberg *et al.* 2003, Zeyda & Stulnig 2007, Zeyda *et al.* 2007, Wentworth *et al.* 2010), promoting the release of

pro-inflammatory and anti-inflammatory adipokines from adipocytes (Tilg & Moschen 2006, Zeyda *et al.* 2007). In this regard, several studies have profiled adipokine expression and secretion in visceral adipose tissue (VAT) and recent proteomic analysis of adipose tissue secretome has identified over 600 adipokines (Lehr *et al.* 2012). In addition, adipokines are also secreted from subcutaneous adipose tissue (SAT) (Skurk *et al.* 2007, Blaber *et al.* 2012, Pellegrinelli *et al.* 2015). Considering that SAT represents a large proportion of total adipose tissue (Rossi *et al.* 2011, Rosqvist *et al.* 2017), SAT-derived adipokines are likely important contributors to tissue crosstalk and systemic inflammatory burden.

The functional role of the adipokines, leptin and adiponectin, as mediators of metabolic health and insulin sensitivity are well described. However, at present the functional role of many novel adipokines in regulating human insulin sensitivity and glucose handling is poorly understood (Nicholson *et al.* 2018). Partly this is because despite skeletal muscle being the major organ for insulin-stimulated glucose uptake (Thiebaud *et al.* 1982), the expression and functional role of these adipokines in human skeletal muscle has not been studied (Nicholson *et al.* 2018). Given that age is a risk factor for the onset of type 2 diabetes (Kalyani *et al.* 2017), understanding the effect of these different adipokines on skeletal muscle insulin sensitivity, particularly in older individuals, is important in determining the potential to target them therapeutically. Of the recently identified novel adipokines, one of the most interesting is vaspin (SERPINA12), a 47 kDa protein, which was first reported in the VAT of the genetically obese OLETF rat (Hida *et al.* 2000). Importantly, several different animal models have recently implicated vaspin as an adipokine that functions to promote insulin sensitivity during metabolic stress. In a diabetic mouse model, administration of recombinant vaspin increased insulin sensitivity and glucose tolerance, whilst reducing the expression of pro-inflammatory adipokines including TNF- α and resistin and increasing the expression of adiponectin (Hida *et al.* 2000). Similar increases in insulin sensitivity have been reported in both db/db and C57BL6 mice following administration with recombinant vaspin (Heiker *et al.* 2013), whilst transgenic mice overexpressing vaspin display improved glucose tolerance and are protected from obesity when challenged with a high-fat diet (Nakatsuka *et al.* 2012).

Currently, very little is known with regard to the expression and secretory profile of vaspin in humans, or its functional role in human skeletal muscle tissue. However, serum concentrations of vaspin have been reported to be

associated with insulin resistance in both non-diabetic and type 2 diabetic patient cohorts (Youn *et al.* 2008, Aust *et al.* 2009, Teshigawara *et al.* 2012, Jian *et al.* 2014), and its expression has been detected in the SAT of obese but not lean individuals (Kloting *et al.* 2006), supporting the notion that vaspin is a key adipokine in mediating metabolic health and insulin sensitivity (Jian *et al.* 2014). Therefore, the aim of this study was to examine the expression of vaspin in human skeletal muscle and SAT in elderly individuals of varying adiposity, and to determine the functional effect of recombinant human vaspin on insulin signalling and glucose uptake in human skeletal muscle tissue.

Materials and methods

Human samples

Gluteus maximus skeletal muscle, SAT and blood samples were obtained from 21 lean (BMI 22.8 ± 0.3 , age 71 ± 1.6 years) and 17 obese (BMI 34.5 ± 0.9 , age 66 ± 2 years) elderly age-matched individuals undergoing elective hip-replacement surgery at the Royal Orthopaedic Hospital, Birmingham, UK, and Russells Hall Hospital, Dudley, UK. Diabetic patients and those taking anti-inflammatory medication within 2 weeks prior to surgery were excluded from the study. Skeletal muscle biopsies were also collected from $n=7$ young lean individuals. Informed consent was obtained from all patients prior to sample collection and full ethical approval for the study was obtained from the Research Ethics Committee (NRES 13/NE/0222) in line with the Declaration of Helsinki.

Sample collection, processing, storage and subsequent experimental procedures were carried out in compliance with Human Tissue Authority guidelines under the Human Tissue Act (2004). Serum was obtained from blood samples (5 mL) taken at the time of surgery by allowing them to clot at room temperature for 20–30 min, followed by centrifugation at 1620g for 10 min. Patient characteristics are detailed in Table 1.

Isolation of primary human myoblasts and their differentiation into myotubes

Skeletal muscle samples (~200 mg) were sliced with a scalpel, placed in 5 mL of 0.05% trypsin-EDTA solution and rotated in an incubator (37°C, 5% CO₂) for 15 min. Trypsin was inactivated by the addition 5 mL of myoblast growth media (Ham's F10 nutrient mix, supplemented with

Table 1 Patient characteristics.

	Lean	Obese	P value
<i>n</i>	21	17	
Male/female (<i>n</i>)	9/12	10/7	
Age	70.6 ± 1.6	65.8 ± 2.1	0.0718
BMI	22.8 ± 0.3	34.5 ± 0.9	<0.0001
Body fat %	23.6 ± 3.0	38.6 ± 2.1	0.0006
Weight (kg)	61.5 ± 2.7	99.2 ± 3.3	<0.0001
Waist circumference (cm)	81.6 ± 2.9	111.0 ± 2.2	<0.0001
Hip circumference (cm)	95.9 ± 1.9	115.0 ± 2.2	<0.0001
Waist: hip	0.85 ± 0.02	0.95 ± 0.02	0.004
%HbA1c	5.4 ± 0.1	5.7 ± 0.07	0.11

20% HyClone research-grade foetal bovine serum and 1% penicillin and streptomycin). The solution was centrifuged for 5 min at 2000g and the resulting pellet re-suspended in 12 mL of myoblast growth medium before transfer to an uncoated T75 cell culture flask for 20 min. Finally, the solution was transferred to a T75 cell culture flask pre-coated with 0.2% gelatine. Myoblast growth medium was replaced every 48 h.

For experimentation, myoblasts were grown to confluence (5–7 days) and differentiation into myotubes was induced by replacing myoblast growth media with differentiation media (Ham's F10 nutrient mix (Sigma-Aldrich), supplemented with 6% horse serum (Sigma-Aldrich) and 1% penicillin and streptomycin. Differentiation media was replaced every second day. All experiments were conducted on the 8th day of differentiation. Myotubes were immunostained (Fig. 3A) for desmin as previously described (O'Leary *et al.* 2017).

Generation of adipose and muscle-conditioned media

SAT or skeletal muscle derived from lean and obese subjects was incubated at 37°C, 5% CO₂ in serum-free culture media (Ham's F10 nutrient mix, Sigma-Aldrich) at a ratio of 1 g:10 mL for up to 24 h. In the case of adipose tissue, larger samples were divided into segments of ~1 g to ensure that the surface area of adipose tissue exposed to medium remained approximately constant. For time course analysis of secreted vaspin, 50 µL aliquots of conditioned media were taken hourly for 6 h and then again at 24 h. Supernatants were removed and stored at –80°C for western blot analysis.

RNA extraction and gene expression analysis

Snap-frozen skeletal muscle and SAT samples (~100 mg) were first ground into a fine powder using a pestle and mortar under liquid nitrogen. Powdered tissue was

immediately transferred to 1 mL of TRIzol reagent (Invitrogen) and homogenised using a Qiagen Tissue Ruptor (Qiagen). Primary human myotubes were lysed in 1 mL of TRIzol reagent (Life Technologies).

RNA was extracted as described in the manufacturer's protocol. RNA was re-suspended in 30 µL of RNase-free water (Life Technologies) and heated at 55°C for 10 min. RNA was quantified using a NanoDrop 2000 (Life Technologies). Relative mRNA expression was determined by Quantitative Real-Time Polymerase Chain (qRT-PCR), performed using Precision™ OneStepPLUS qRT-PCR (with SYBR-green) mastermix (Primerdesign, UK), 5 ng total RNA and primers as described in Supplementary Table 1 (see section on [supplementary data](#) given at the end of this article). All reactions were performed using a BioiRd sfx cycler (Bio-Rad).

Immunoblotting analysis

Aliquots of powdered skeletal muscle tissue, SAT and primary human myotubes were lysed in RIPA buffer (Life Technologies) containing Phosphatase Inhibitor Cocktail 3 (1:100, Sigma-Aldrich) and Protease Inhibitor Cocktail (1:100, Sigma-Aldrich). After addition of RIPA buffer, samples were placed on ice for 20 min. Total protein in cell and tissue lysates was quantified by performing a BCA assay (Life Technologies) and protein samples prepared for gel electrophoresis by diluting in loading buffer consisting of 2-mercaptoethanol (Sigma-Aldrich), 4× Laemmli sample buffer and double distilled H₂O, followed by boiling for 10 min in a heat block. For adipose and muscle-conditioned media samples, 10 µL of conditioned media diluted in loading buffer was loaded per sample. For cell lysates, 10–15 µg of protein was loaded per sample depending on the particular western blot.

Samples were loaded into a 5% stacking gel and separated by performing 12% SDS-PAGE. Protein was transferred to a methanol-activated PVDF membrane

(0.2 μ m) using a Trans-Blot Turbo system (Bio-Rad). Membranes containing protein samples from tissue and primary human myotubes were blocked with TBS-T containing 5% BSA. Membranes containing protein samples from serum and adipose conditioned media were blocked with 5% milk, 2% BSA and 0.5% H₂O₂.

Membranes were immuno-probed overnight at 4°C, with primary antibodies as described in Supplementary Table 2, followed by incubation for 2 h at RT with the appropriate secondary antibody (HRP-linked anti-rabbit/anti-mouse IgG secondary antibody (1:10,000; GE Healthcare)). Blots were developed using Amersham ECL Prime (GE Healthcare), and imaged using a ChemiDoc MP System (Bio-Rad) (Supplementary Figs 1, 2, 3 and 4). Densitometry analysis of bands was performed using an open-source, public domain software package (ImageJ v1.47).

Vaspin ELISA

Serum vaspin was measured using a commercially available human vaspin ELISA kit (AdipoGen Life Sciences), following the manufactures instructions. Serum samples were diluted 1:4 in ELISA buffer and the plate was read on a BioTek EL808 microtiter plate reader (BioTek, Swindon, UK).

MesoScale immunoassays

Myotubes were cultured in 96-well plates and stimulated with 10 nM human insulin (I0908, Sigma-Aldrich), 100 ng/mL of recombinant human vaspin (R&D Systems) or 100 ng/mL recombinant human vaspin immediately followed by 10 nM insulin. Cells were lysed in 90 μ L MSD lysis buffer (MesoScale Discovery, Gaithersburg, Massachusetts, USA) containing Phosphatase Inhibitor Cocktail 3 (1:100 dilution, Sigma-Aldrich) and a Protease Inhibitor Cocktail (1:100 dilution, Sigma-Aldrich). Insulin receptor, IGF1 receptor and AKT (thr308) phosphorylation, as a percentage of total protein, was determined using MesoScale Discovery phospho and total protein assays, performed according to the manufacturer's instructions and detected on the SECTOR Imager 6000 (MesoScale Discovery).

Glucose uptake assays

Glucose uptake in primary human myotubes was quantified using either a radiometric or a

fluorometric assay. For the radiometric assay, obese myotubes were cultured in 6-well plates and either left unstimulated or were pre-incubated for 24 h with vaspin (100 ng/mL). The next day myotubes were washed twice in warm PBS and incubated in serum-free media (Ham's F10) for 2 h. Myotubes were washed a further two times before incubation with 2 mL reaction buffer (138 mM NaCl, 1.85 mM CaCl₂, 1.3 mM MgSO₄, 4.8 mM KCl, 50 mM HEPES, pH 7.4, 0.2% (W/V) BSA) for 45 min at 37°C. Myotubes were then incubated with or without insulin (100 nM) for 30 min on a plate warmer at 37°C before the addition of 250 μ L of 27.8 kBq [³H]-2-DOG and 10 μ M 2-DOG at timed intervals to each well for 15 min. The buffer was aspirated with a vacuum pump and myotubes were washed three times with ice cold PBS containing 10 mM glucose. Myotubes were then lysed in 500 μ L 0.5 M NaOH and 0.1% SDS then transferred to scintillation vials and 5 mL liquid scintillation fluid was added. Samples were vortexed and assayed for [³H]-2-DOG uptake expressed as disintegrations/min/well using a β -counter.

For the fluorometric assay, lean and obese myotubes cultured in 96-well plates were washed three times in PBS before incubation with glucose-free DMEM media (Gibco) for 3 h. Myotubes were washed a further three times before incubation with 100 μ M 2-NBDG glucose (Sigma), diluted in glucose-free media with or without 100 nM insulin, for 30 min. Myotubes were subject to a further three washes with PBS before final addition of 100 μ L PBS/well. Fluorescence was measured by excitation at 485 nm and emission at 528 nm using a Synergy 2 Multi-Detection Microplate Reader (BioTek). Untreated myotubes were included to correct for myotube auto-fluorescence. Five biological replicates were performed per condition for each cell line.

Quantification of GLUT4 translocation by flow cytometry

Quantification of GLUT4 translocation to the cell membrane was determined by flow cytometry in myoblasts as previously described (Koshy *et al.* 2010). In brief, primary human myoblasts (10⁵ cells/condition) from obese subjects (*n*=5) were treated with either vaspin (100 ng/mL, 15 min) or insulin (100 nM, 15 min). Post-treatment, cells were washed with PBS and stained for GLUT4 (Anti-GLUT4 antibody ab65267, Abcam. 0.05 μ g/10⁵ cells, diluted in 2% BSA PBS) on ice for 20 min. A second wash with PBS was then preformed,

before addition of the secondary antibody (Alexa Fluor 488 goat anti-mouse IgG, Invitrogen, Thermo Fisher Scientific. 5 µg/mL diluted in 2% BSA PBS) for 20 min on ice. Cells were then washed in PBS and fixed with paraformaldehyde (Medium A, Life Technologies) for 20 min at RT. Following a single wash in PBS cells were re-suspended in PBS and the relative surface expression of GLUT4 quantified by measuring the mean fluorescence intensity (MFI) of a minimum 1500 cells/condition using an AccuriC6™ bench top flow cytometer (BD Biosciences).

Statistical analysis

Data analysis was carried out using GraphPad Prism v5 statistical package. The normality of data was established by a Shapiro–Wilk test. Significance was determined by parametric *t*-tests and by ANOVA with Dunnett's post-hoc tests where appropriate, and are detailed in the figure legends. The correlation of vaspin and GRP78 expression with BMI was assessed by determining the Pearson correlation coefficient. Data is presented as mean ± s.e.m., with a *P* value of <0.05 considered statistically significant.

Results

The expression of vaspin and its putative receptor GRP78 are increased in the skeletal muscle and SAT of obese individuals

We first examined the mRNA expression of *vaspin* and its putative plasma membrane receptor *GRP78* (*HSPA5*) in both skeletal muscle and SAT in humans of varying BMI. *Vaspin* mRNA expression was significantly greater in both SAT (2.5-fold, *P*<0.01) and skeletal muscle (1.5-fold, *P*<0.05) of obese subjects in comparison to lean subjects (Fig. 1A and B) and demonstrated a significant positive correlation with BMI (Fig. 1E) and skeletal muscle (Fig. 1F). Similarly, expression of *GRP78* was significantly greater in both SAT (1.5-fold, *P*<0.05) and skeletal muscle (1.8-fold, *P*<0.05) of obese subjects in comparison to lean subjects (Fig. 1C and D) and was positively correlated with BMI in both tissue types (Fig. 1G and H).

Vaspin is rapidly secreted from human adipose tissue and muscle tissue and is detectable systemically in both lean and obese individuals

To investigate the potential for vaspin to signal between human SAT and skeletal muscle we first examined by

Figure 1

Vaspin and GRP78 mRNA expression are upregulated in subcutaneous adipose tissue and skeletal muscle in obese elderly individuals. (A) The mRNA expression of vaspin in SAT of lean (*n* = 21) and obese (*n* = 17) elderly individuals. (B) The mRNA expression of vaspin in skeletal muscle of lean (*n* = 4) and obese (*n* = 4) elderly. (C) The mRNA expression of GRP78 in SAT of lean (*n* = 8) and obese (*n* = 9) elderly. (D) The mRNA expression of GRP78 in skeletal muscle of lean (*n* = 7) and obese (*n* = 9) elderly. (E) Correlation of vaspin mRNA expression in SAT with BMI. (F) Correlation of vaspin mRNA expression in skeletal muscle with BMI. (G) Correlation of GRP78 mRNA expression in SAT with BMI. (H) Correlation of GRP78 mRNA expression in skeletal muscle with BMI. Expression of mRNA was quantified by qRT-PCR, and normalised using GAPDH. Data are represented as mean ± s.e.m. *signifies *P* < 0.05, ***signifies *P* ≤ 0.001, as determined by unpaired *t*-tests.

immunoblotting the *ex vivo* secretion of vaspin from SAT and skeletal muscle into culture media over a 24 h time course. Vaspin was detected in serum-free culture media that had been conditioned with either SAT or skeletal muscle for 1 h, indicating that vaspin is rapidly secreted from both tissue types. The amount of vaspin detected in both SAT and skeletal muscle-conditioned media

increased up to 6 h and was maintained for the duration of 24 h (Fig. 2A and B). Further, a significantly greater level of vaspin was detected in SAT conditioned media of obese ($n=16$) in comparison to lean ($n=17$) at 24 h (Fig. 2C). We then examined by ELISA whether vaspin could be detected systemically in human sera, and whether there was a difference in the systemic concentration of vaspin

Figure 2

Vaspin is rapidly secreted from human subcutaneous adipose tissue and systemically is elevated in obese individuals. Detection of vaspin protein in (A) SAT conditioned media and (B) skeletal muscle-conditioned media in lean and obese subjects over a 24 h time course, as measured by immunoblotting. 10 μ L adipose or skeletal muscle-conditioned media was loaded per sample lane. Bars represent mean densitometric units $\pm$ s.e.m. of immunoblots from $n=3$ subjects analysis. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, significantly different from time = 0 media control sample as determined by one-way ANOVA with Dunnett's post-hoc tests. (C) Densitometric analysis of vaspin protein expression in adipose conditioned media at 24 h from lean ($n=17$) and obese ($n=16$) subjects as measured by immunoblotting. 10 μ L of adipose conditioned media was loaded per sample lane. $=P < 0.05$, as determined by unpaired t-test. (D) Detection of vaspin protein in the serum of lean ($n=8$ lean; $n=8$ obese) and female ($n=8$ lean; $n=7$ obese) subjects by ELISA. (E) Pearson correlation of serum vaspin with BMI in males. (F) Pearson correlation of serum vaspin with BMI in females.

between lean ($n=16$) and obese ($n=15$) individuals. Vaspin was detected in the serum of both lean and obese individuals but there was no significant difference between levels found in obese individuals in comparison to lean individuals in either males or females (Fig. 2D). However, serum vaspin was on average higher in obese females compared to lean females. Furthermore, although there was no significant correlation between serum vaspin and BMI in males (Fig. 2E), in females we found a significant positive correlation ($R^2=0.267$, $P<0.05$) with BMI (Fig. 2F).

The effect of vaspin on insulin signalling pathways in primary human myotubes

We next examined the effect of stimulating primary human myotubes (Fig. 3A) with recombinant human vaspin on insulin signalling pathways. First, lean primary myotubes were stimulated with recombinant vaspin (100 ng/mL) acutely for either 5, 10 or 15 min and AKT activity (phosphorylation) quantified using MesoScale immunoassays (MesoScale Discovery). Myotubes stimulated with vaspin for either 10 or 15 min showed a significant threefold increase in phosphoAKT (threonine³⁰⁸)/total AKT expression (Fig. 3B), which along with activation of the other AKT phosphorylation site (serine⁴⁷³) was validated by immunoblotting ($n=4$ patient replicates) (Fig. 3C, D and E). To investigate the mechanism of the vaspin-mediated induction in basal AKT activity we examined whether acute or chronic stimulation of human myotubes with vaspin led to activation of either the insulin receptor or the IGF receptor. As expected, 15 min of insulin stimulation alone induced a significant increase in the phosphorylation of both the insulin receptor and the IGF receptor (Fig. 3F and G). However, stimulation of myotubes with vaspin for either 15 min or chronic stimulation for 24 h induced no phosphorylation of either the insulin receptor or the IGF receptor (Fig. 3F and G), indicating that vaspin did not directly affect activation of upstream insulin signalling. Given these findings, we then examined whether vaspin affected the activity of downstream insulin signalling by determining the activity status of PI3K by immunoblotting. Acute stimulation of primary human myotubes ($n=4$ patients) with vaspin (100 ng/mL) induced a transient increase in phosphorylation of PI3K between 10 and 15 min as determined by immunoblotting (Fig. 3H and I).

Vaspin induces the expression and translocation of GLUT4 protein and promotes glucose uptake in the presence of insulin in human myotubes

Following these data, and with the observation that vaspin-induced activation of downstream insulin signalling components, we then investigated the functional metabolic role of vaspin by examining whether vaspin affected GLUT4 expression and glucose uptake in primary human myoblasts and myotubes from obese subjects.

First, we examined whether there was a difference in skeletal muscle GLUT4 mRNA expression between old obese ($n=8$), old lean ($n=8$) and young ($n=7$) subjects. Compared to young subjects, GLUT4 expression was 69% lower in the skeletal muscles from old obese subjects ($P<0.05$; Fig. 4A). In line with the relatively low expression of GLUT4 in old obese muscle, myotubes derived from old obese subjects also displayed a blunted glucose uptake response to insulin (100 nM, 30 min), in comparison to myotubes cultured from old lean subjects (Fig. 4B).

Stimulation of obese myotubes with vaspin (100 ng/mL) for 24 h induced a significant ($P<0.05$) ~fivefold increase in the expression of GLUT4 mRNA (Fig. 4C), which translated into a significant ($P<0.05$) increase in GLUT4 protein (Fig. 4D). Furthermore, stimulation of primary human myoblasts with either insulin (100 nM) or vaspin (100 ng/mL) for 15 min caused a significant ($P<0.05$) increase in GLUT4 protein surface expression, compared to non-stimulated myoblasts, indicative of an increase in GLUT4 protein translocation (Fig. 4E).

We then investigated whether these vaspin-mediated effects on both the expression and translocation of GLUT4 were sufficient to impact on glucose uptake in previously insulin-insensitive obese myotubes. Primary human myotubes from old obese subjects that had not been pre-treated with vaspin showed no increase in glucose uptake in response to 30 min of insulin stimulation (100 nM), compared to unstimulated control (Fig. 4F). However, 30 min insulin stimulation significantly increased glucose uptake in vaspin pre-treated myotubes, compared to control myotubes (Fig. 4F). Finally, since p38 and AMPK activation have been implicated in promoting GLUT4 expression we examined the effect of vaspin stimulation on their activation status. Acute stimulation of primary human myotubes (0–15 min) with 100 ng/mL vaspin induced a significant activation of both p38 ($n=4$ biological replicates) and AMPK ($n=4$ biological replicates), as measured by immunoblotting (Fig. 4G, H and I).

Figure 3

Vaspin activates downstream insulin signalling pathways in primary human myotubes. (A) Representative isolated human myoblasts and differentiated myotubes immunofluorescently stained with desmin and viewed using a 20 $\times$ objective. (B) Effect of acute stimulation (0, 5, 10, 15 min) of primary human myotubes with recombinant human vaspin (100 ng/mL) on AKT^{Thr308} phosphorylation measured by mesoscale analysis ($n = 4$ biological replicates, 2 from male and 2 from female). (C) Representative immunoblots of AKT^{Ser473} and AKT^{Thr308} phosphorylation in untreated and vaspin (100 ng/mL)-stimulated myotubes after 0, 5, 10 and 15 min stimulation ($n = 4$ primary donors: 2 male, 2 female, 15 μ g of total protein was loaded per sample). (D) Densitometric analysis of AKT^{Thr308} western blots normalised to Total AKT protein ($n = 4$). (E) Densitometric analysis of AKT^{Ser473} western blots relative to Total AKT protein ($n = 4$). (F) Effect of insulin (0–30 nM, 30 min) and acute (15 min) or chronic (24 h) vaspin stimulation (100 ng/mL) on the phosphorylation of insulin receptor and (G) IGF receptor as measured by mesoscale analysis ($n = 16$ biological replicates from 8 primary donors: 4 male, 4 female). (H) Time course of acute vaspin stimulation (100 ng/mL) on the activation of PI3K assessed by immunoblotting ($n = 4$ primary donors: 1 male, 3 female, 15 μ g total protein was loaded per sample). (I) Densitometric analysis of Phospho-PI3K western blots normalised to total PI3K. Data are represented as mean $\pm$ S.E.M. Data was analysed using one-way ANOVA with Dunnett's post-hoc tests. *signifies $P < 0.05$, **signifies $P < 0.01$, ***signifies $P < 0.001$.

Discussion

With the current dearth of human data on the adipokine vaspin, this study is the first to characterise the expression of vaspin in both skeletal muscle and adipose tissue in elderly individuals of varying BMI and to report the functional effect of vaspin on human skeletal muscle insulin signalling pathways and glucose uptake.

Previously, vaspin mRNA has been reported to be detectable in only around 15% of human SAT samples, with no expression reported in SAT of lean subjects (Kloting *et al.* 2006). In the present study, we detected vaspin mRNA in both SAT and skeletal muscle from both lean and obese individuals. However, vaspin was more highly expressed in the SAT and skeletal muscles from obese individuals and in both tissue types its expression positively correlated with

BMI. We also found that vaspin protein was rapidly secreted from both human SAT and skeletal muscle tissue, with the quantity secreted from obese tissues being greater than from lean tissues. Together these data support the findings from rodent studies that describe an increase in vaspin tissue expression with obesity (Hida *et al.* 2000, Heiker *et al.* 2013). It is important to note that our finding that vaspin expression in adipose and muscle tissue was increased with obesity was in patients without type 2 diabetes. Gene array data in the GEO database does not reveal any significant difference in vaspin adipose tissue expression between patients with or without insulin resistance or in those with type 2 diabetes compared to individuals with normal glucose tolerance (Edgar *et al.* 2002). Furthermore, a recent report found that circulatory levels of vaspin in morbidly obese individuals declined following weight loss induced by laparoscopic

Figure 4

Vaspin induces GLUT4 expression and sensitises insulin-mediated glucose uptake in primary human myotubes. (A) GLUT4 mRNA expression relative to GAPDH in skeletal muscle tissue derived from lean young ($n = 7$), lean old ($n = 8$) and obese old ($n = 8$) subjects. $*P < 0.05$, significantly different between young and old obese as determined by one-way ANOVA with Dunnett's post-hoc tests. (B) Effect of insulin (100 nM, 30 min) on 2-NBDG glucose uptake in primary human myotubes derived from lean ($n = 4$ females) and obese ($n = 3$ females) subjects. $*P < 0.05$, significantly different from unstimulated control as determined by two-way ANOVA. (C) GLUT4 mRNA expression in primary human myotubes from obese subjects stimulated for 24 h with recombinant vaspin (100 ng/mL) or left untreated ($n = 5$ primary donors: 2 male, 3 female). Expression was determined by qRT-PCR and normalised to GAPDH.

$*P < 0.05$, significantly different from unstimulated control, as determined by t -test. (D) GLUT4 protein expression as measured by immunoblotting in primary human myotubes from obese subjects stimulated for 24 h with vaspin (100 ng/mL) or left untreated ($n = 6$ primary donors: 2 male, 4 female). $*P < 0.05$, significantly different from unstimulated control, as determined by t -test. (E) Primary human myoblast membrane localised GLUT4 expression in response to insulin (100 nM 15 min), or vaspin (100 ng/mL 15 min), ($n = 5$ obese primary donors: 2 male, 3 female). Relative surface expression of GLUT4 was quantified by measuring the MFI in a minimum of 1500 cells/condition by flow cytometry. $*P < 0.05$, significantly different from unstimulated control as determined by one-way ANOVA with Dunnett's post-hoc tests. (F) Effect of 24 h exposure of primary obese myotubes ($n = 3$, female donor) to recombinant vaspin (100 ng/mL) on basal and insulin-stimulated radiolabelled glucose uptake ($[^3H]$ -2-DOG). $*P < 0.05$, significantly different from unstimulated control as determined by one-way ANOVA with Dunnett's post-hoc tests. (G) Representative immunoblots for phospho and total p38 ($n = 4$ primary donors) and phospho AMPK and total AMPK ($n = 4$ primary donors: 1 male, 3 female) in untreated and vaspin (100 ng/mL)-stimulated myotubes after 0, 5, 10 and 15 min stimulation. 10 μ g of total protein was loaded per sample. (H) Densitometric quantification of phospho-p38 immunoblots relative to total p38 protein. Bars present mean densitometric units $\pm$ S.E.M. ($n = 4$). $*P < 0.05$, significantly different from unstimulated control as determined by one-way ANOVA. (I) Densitometric quantification of phospho-AMPK immunoblots relative to total AMPK. Bars present mean densitometric units $\pm$ S.E.M. ($n = 3$). $**P < 0.01$, significantly different from unstimulated control as determined by one-way ANOVA.

sleeve gastrectomy (Ibrahim *et al.* 2018). These findings, together with our data here, support the notion that vaspin expression in humans is dependent on BMI irrespective of diabetic status.

Contrary to previous reports (Youn *et al.* 2008), we found no significant difference in serum levels of vaspin in obese individuals compared to lean. This was despite the greater expression and secretion of vaspin from obese

SAT of these individuals. This might suggest that elevated secretion of vaspin from SAT in obese individuals is more likely to have localised effects rather than systemic effects on distal tissues. However, it should be noted that serum concentrations of vaspin were variable and therefore with a larger cohort the higher on average concentration of vaspin in obese individuals may have reached statistical significance.

A number of previous publications have examined systemic levels of vaspin in males and females of varying BMI, with contrasting results. In individuals aged 17–79 it was found that serum vaspin was significantly higher in obese male subjects compared to lean male subjects, but was not significantly different between obese and lean females (Youn *et al.* 2008). However, the study by Esteghamati *et al.* found that serum vaspin levels positively correlated with BMI in both males and females (Esteghamati *et al.* 2014). In addition, higher levels of serum vaspin were reported in females compared to males in individuals with normal glucose tolerance, but no gender difference was seen in individuals with type 2 diabetes (Youn *et al.* 2008). However, Seeger *et al.* examined serum vaspin levels in diabetic and non-diabetic patients in both controls and in those patients on chronic haemodialysis (CD) with BMI between 26 and 30 and found that vaspin was higher in females and furthermore that gender was an independent predictor of circulating vaspin concentrations (Seeger *et al.* 2008). Together these observations could reflect sex dimorphism in SAT distribution and quantity (Fuente-Martin *et al.* 2013, White & Tchoukalova 2014). It is known for example that females predominantly accumulate more SAT than males (Kotani *et al.* 1994), and thus vaspin may play a greater role in mediating glucose homeostasis in females than in males. Indeed, some studies have previously reported that the prevalence of metabolic syndrome is higher in females than in males (Beigh & Jain 2012), with central adiposity being a greater risk factor for metabolic diseases in females (Li *et al.* 2006, Holliday *et al.* 2011).

Contrary to the above studies, we found no significant difference between serum vaspin concentration between males and females in either normal weight or obese individuals. Furthermore, and contrary to the findings of Esteghamati *et al.* (2014) we did not find a significant correlation between BMI and vaspin levels in males. However, we did observe that serum vaspin in females significantly correlated with BMI. These disparities may be a reflection of the relatively smaller sample size used in our study but also likely reflects differences between subject cohorts. For example, the male subjects studied by

Youn *et al.* (2008) had a mean age of 39 years, whilst both the male and female subjects studied by Esteghamati *et al.* (2014) had a mean age of 49 years, considerably lower than the mean age of subjects in this study.

Vaspin-mediated activation of PI3K/AKT has been reported previously in several other cell types, including pancreatic cells (Liu *et al.* 2017), 3T3-L1 preadipocytes (Liu *et al.* 2015) and endothelial progenitor cells (Sun *et al.* 2015). Furthermore, it was recently reported that vaspin promotes the PI3K/AKT signalling pathway leading to increased GLUT4 protein expression in rats fed a high-fat diet (Liu *et al.* 2018) and can improve glucose tolerance in mice (Nakatsuka *et al.* 2012). Therefore, our demonstration that vaspin induces activation of PI3K-AKT signalling and increases insulin sensitivity in obese human myotubes is significant. These vaspin-induced effects appear to occur independently of upstream insulin signalling, since vaspin had no direct effect on either the insulin receptor or IGF-1 receptor phosphorylation status. Activation of PI3K/AKT signalling is known to promote GLUT4 translocation and glucose uptake in skeletal muscle cells (Dugani & Klip 2005), and here we report that vaspin promotes GLUT4 expression and translocation and facilitates glucose uptake in human obese myotubes. Notably, 15 min stimulation of primary human myoblasts derived from obese subjects with vaspin was able to significantly increase GLUT4 surface translocation to a similar magnitude to that observed with insulin stimulation. This finding may be of clinical significance given that GLUT4 translocation is impaired in type 2 diabetes patients with insulin insensitivity (Maria *et al.* 2015). Indeed, since our data shows that vaspin induces insulin signalling independent of activating the insulin receptor this could provide a novel route to therapeutically improve glucose maintenance in insulin-resistant individuals.

Despite being able to promote GLUT4 translocation we found that insulin stimulation of obese myotubes did not result in glucose uptake. Previous studies in rats have demonstrated that GLUT4 expression declines with age (dos Santos *et al.* 2012) and obesity (Kahn & Pedersen 1993). Here we report for the first time in humans that muscle tissue derived from elderly obese individuals displayed a significantly lower expression of *GLUT4* mRNA in comparison to young lean individuals. The retention of this phenotype in primary human myotubes from elderly obese subjects may therefore explain the blunted insulin response observed at baseline.

Importantly, prolonged 24 h pre-treatment of obese myotubes with vaspin sensitised them to insulin-mediated

glucose uptake. This sensitisation is likely due to vaspin increasing the bioavailable intracellular pool of GLUT4. Previous studies in 3-T3-L1 adipocytes (Liu *et al.* 2015) and in mice (Hida *et al.* 2005) have reported that vaspin induces *GLUT4* expression. Here, we report for the first time that vaspin significantly induces *GLUT4* mRNA and *GLUT4* protein expression in human skeletal muscle. Importantly, we also demonstrate that vaspin is able to activate both AMPK and p38 signalling in primary human myotubes. AMPK activation has previously been reported to upregulate *GLUT4* expression in primary human myotubes (McGee *et al.* 2008), while p38 is known to regulate transcription factors that control the expression of *GLUT4* (Niu *et al.* 2003, Montessuit *et al.* 2004). Activation of these signalling pathways may therefore be a potential mechanism to explain the vaspin-induced upregulation in *GLUT4* mRNA and protein expression observed.

However, it should be noted that primary human myotubes in culture elicit relatively low insulin-stimulated glucose uptake (Montell *et al.* 2001, Al-Khalili *et al.* 2003, Aas *et al.* 2004), compared to skeletal muscle tissue. This could be due to low basal expression of *GLUT4*, which has been attributed to denervation (Chowdhury *et al.* 2005, Jensen *et al.* 2009) and the subsequent absence of contraction. Therefore, in our model system, treatment of myotubes with vaspin may only be increasing the pool of bioavailable *GLUT4* towards physiological levels. Whether vaspin administration in humans *in vivo* would have the same effect remains to be seen.

A cell surface receptor for vaspin has yet to be fully elucidated. One possible mechanism is that vaspin signals through *GRP78*, a protein that has an important intracellular regulatory role during cellular ER stress (Lee 2005, Matsuo *et al.* 2013). However, recent evidence shows *GRP78* also functions as a cell surface receptor, with membrane localised *GRP78* binding vaspin and in turn promoting AKT and AMPK signalling in H-4-II-E-C3 cells (Nakatsuka *et al.* 2012). Here, we show *GRP78* expression is present in both SAT and skeletal muscle in older individuals. Expression of *GRP78* was found to be significantly greater in both SAT and skeletal muscle of obese subjects and displayed a positive correlation with BMI in each case. This is concurrent with the results of Khadir *et al.*, who also found increased *GRP78* expression in SAT of obese humans (Khadir *et al.* 2016). Chronic ER stress can be induced by obesity (Yilmaz 2017) and is associated with inflammatory adipose tissue (Kawasaki *et al.* 2012), and this may explain the increased *GRP78* expression in muscle and adipose tissue of obese individuals in our present study. Additionally, ER stress

has been shown to promote re-localisation of *GRP78* to the cell membrane, thus increasing ligand-binding capacity (Zhang *et al.* 2010). Whether the functional effects of vaspin we report here in human myotubes are dependent on *GRP78* signalling requires further study.

In summary, this study shows that vaspin is directly secreted from both human SAT and skeletal muscle and its expression is increased with increasing adiposity in older people. Functionally, vaspin induces PI3K/AKT activation, increases both *GLUT4* expression and translocation and promotes insulin-stimulated glucose uptake in primary obese older human myotubes. This data support a role for vaspin as a protective adipokine in the development of insulin resistance in elderly obese individuals. Further studies are needed to identify the mechanism of action of vaspin as this may provide a novel therapeutic target to improve insulin sensitivity independent of the insulin receptor.

Supplementary data

This is linked to the online version of the paper at <https://doi.org/10.1530/JOE-18-0528>.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

T N was funded by a BBSRC Case PhD studentship with MedImmune/AstraZeneca (BB/N504002/1).

Acknowledgements

The authors thank the study participants and Research Nurse support at Russells Hall Hospital (Elise Cooke). We also thank the surgeons, Matthew Revell, David Dunlop, Andrew Pearson and Sohail Quraishi who facilitated this work.

References

- Aas V, Kase ET, Solberg R, Jensen J & Rustan AC 2004 Chronic hyperglycaemia promotes lipogenesis and triacylglycerol accumulation in human skeletal muscle cells. *Diabetologia* **47** 1452–1461. (<https://doi.org/10.1007/s00125-004-1465-9>)
- Al-Khalili L, Chibalin AV, Kannisto K, Zhang BB, Permert J, Holman GD, Ehrenborg E, Ding VD, Zierath JR & Krook A 2003 Insulin action in cultured human skeletal muscle cells during differentiation: assessment of cell surface *GLUT4* and *GLUT1* content. *Cellular and Molecular Life Sciences* **60** 991–998. (<https://doi.org/10.1007/s00018-003-3001-3>)

- Aust G, Richter O, Rohm S, Kerner C, Hauss J, Kloting N, Ruschke K, Kovacs P, Youn BS & Bluher M 2009 Vaspin serum concentrations in patients with carotid stenosis. *Atherosclerosis* **204** 262–266. (<https://doi.org/10.1016/j.atherosclerosis.2008.08.028>)
- Beigh SH & Jain S 2012 Prevalence of metabolic syndrome and gender differences. *Bioinformation* **8** 613–616. (<https://doi.org/10.6026/97320630008613>)
- Blaber SP, Webster RA, Hill CJ, Breen EJ, Kuah D, Vesey G & Herbert BR 2012 Analysis of in vitro secretion profiles from adipose-derived cell populations. *Journal of Translational Medicine* **10** 172. (<https://doi.org/10.1186/1479-5876-10-172>)
- Bluher M 2014 Adipokines – removing road blocks to obesity and diabetes therapy. *Molecular Metabolism* **3** 230–240. (<https://doi.org/10.1016/j.molmet.2014.01.005>)
- Bluher M & Mantzoros CS 2015 From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century. *Metabolism* **64** 131–145. (<https://doi.org/10.1016/j.metabol.2014.10.016>)
- Carey DG, Jenkins AB, Campbell LV, Freund J & Chisholm DJ 1996 Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. *Diabetes* **45** 633–638. (<https://doi.org/10.2337/diab.45.5.633>)
- Chowdhury HH, Jevsek M, Kreft M, Mars T, Zorec R & Grubic Z 2005 Insulin-induced exocytosis in single, in vitro innervated human muscle fibres: a new approach. *Pflügers Archiv* **450** 131–135. (<https://doi.org/10.1007/s00424-004-1378-y>)
- dos Santos JM, Benite-Ribeiro SA, Queiroz G & Duarte JA 2012 The effect of age on glucose uptake and GLUT1 and GLUT4 expression in rat skeletal muscle. *Cell Biochemistry and Function* **30** 191–197. (<https://doi.org/10.1002/cbf.1834>)
- Dugani CB & Klip A 2005 Glucose transporter 4: Cycling, compartments and controversies. *EMBO Reports* **6** 1137–1142. (<https://doi.org/10.1038/sj.embor.7400584>)
- Edgar R, Domrachev M & Lash AE 2002 Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. *Nucleic Acids Research* **30** 207–210. (<https://doi.org/10.1093/nar/30.1.207>)
- Esteghamati A, Noshad S, Mousavizadeh M, Zandieh A & Nakhjavani M 2014 Association of vaspin with metabolic syndrome: the pivotal role of insulin resistance. *Diabetes and Metabolism Journal* **38** 143–149. (<https://doi.org/10.4093/dmj.2014.38.2.143>)
- Fuente-Martin E, Argente-Arizon P, Ros P, Argente J & Chowen JA 2013 Sex differences in adipose tissue: it is not only a question of quantity and distribution. *Adipocyte* **2** 128–134. (<https://doi.org/10.4161/adip.24075>)
- Heiker JT, Kloting N, Kovacs P, Kuettner EB, Strater N, Schultz S, Kern M, Stumvoll M, Bluher M & Beck-Sickinger AG 2013 Vaspin inhibits kallikrein 7 by serpin mechanism. *Cellular and Molecular Life Sciences* **70** 2569–2583. (<https://doi.org/10.1007/s00018-013-1258-8>)
- Hida K, Wada J, Zhang H, Hiragushi K, Tsuchiyama Y, Shikata K & Makino H 2000 Identification of genes specifically expressed in the accumulated visceral adipose tissue of OLETF rats. *Journal of Lipid Research* **41** 1615–1622.
- Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, Hashimoto I, Okada T, Yasuhara A, Nakatsuka A, *et al.* 2005 Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. *PNAS* **102** 10610–10615. (<https://doi.org/10.1073/pnas.0504703102>)
- Holliday KL, McWilliams DF, Maciewicz RA, Muir KR, Zhang W & Doherty M 2011 Lifetime body mass index, other anthropometric measures of obesity and risk of knee or hip osteoarthritis in the GOAL case-control study. *Osteoarthritis and Cartilage* **19** 37–43. (<https://doi.org/10.1016/j.joca.2010.10.014>)
- Ibrahim DM, Mohamed NR, Fouad TA & Soliman AF 2018 Short-term impact of laparoscopic sleeve gastrectomy on serum Cartonectin and vaspin levels in obese subjects. *Obesity Surgery* **28** 3237–3245. (<https://doi.org/10.1007/s11695-018-3306-9>)
- Jensen EB, Zheng DH, Russell RA, Bassel-Duby R, Williams RS, Olson AL & Dohm GL 2009 Regulation of GLUT4 expression in denervated skeletal muscle. *American Journal of Physiology. Regulatory, Integrative and Comparative Physiology* **296** R1820–R1828. (<https://doi.org/10.1152/ajpregu.90651.2008>)
- Jian W, Peng W, Xiao S, Li H, Jin J, Qin L, Dong Y & Su Q 2014 Role of serum vaspin in progression of Type 2 diabetes: A 2-year cohort study. *PLoS One* **9** e94763. (<https://doi.org/10.1371/journal.pone.0094763>)
- Kahn BB & Pedersen O 1993 Suppression of GLUT4 expression in skeletal muscle of rats that are obese from high fat feeding but not from high carbohydrate feeding or genetic obesity. *Endocrinology* **132** 13–22. (<https://doi.org/10.1210/endo.132.1.8419118>)
- Kahn BB & Flier JS 2000 Obesity and insulin resistance. *Journal of Clinical Investigation* **106** 473–481. (<https://doi.org/10.1172/JCI10842>)
- Kalyani RR, Golden SH & Cefalu WT 2017 Diabetes and aging: unique considerations and goals of care. *Diabetes Care* **40** 440–443. (<https://doi.org/10.2337/dci17-0005>)
- Kawasaki N, Asada R, Saito A, Kanemoto S & Imaizumi K 2012 Obesity-induced endoplasmic reticulum stress causes chronic inflammation in adipose tissue. *Scientific Reports* **2** 799. (<https://doi.org/10.1038/srep00799>)
- Khadir A, Kavalakatt S, Abubaker J, Cherian P, Madhu D, Al-Khairi I, Abu-Farha M, Warsame S, Elcum N, Dehbi M, *et al.* 2016 Physical exercise alleviates ER stress in obese humans through reduction in the expression and release of GRP78 chaperone. *Metabolism* **65** 1409–1420. (<https://doi.org/10.1016/j.metabol.2016.06.004>)
- Kloting N, Berndt J, Kralisch S, Kovacs P, Fasshauer M, Schon MR, Stumvoll M & Bluher M 2006 Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. *Biochemical and Biophysical Research Communications* **339** 430–436. (<https://doi.org/10.1016/j.bbrc.2005.11.039>)
- Koshy S, Alizadeh P, Timchenko LT & Beeton C 2010 Quantitative measurement of GLUT4 translocation to the plasma membrane by flow cytometry. *Journal of Visualized Experiments* **45** 2429. (<https://doi.org/10.3791/2429>)
- Kotani K, Tokunaga K, Fujioka S, Kobatake T, Keno Y, Yoshida S, Shimomura I, Tarui S & Matsuzawa Y 1994 Sexual dimorphism of age-related-changes in whole-body fat distribution in the obese. *International Journal of Obesity and Related Metabolic Disorders* **18** 207–202.
- Lee AS 2005 The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress. *Methods* **35** 373–381. (<https://doi.org/10.1016/j.ymeth.2004.10.010>)
- Lehr S, Hartwig S, Lamers D, Famulla S, Müller S, Hanisch FG, Cuvelier C, Ruige J, Eckardt K, Ouwens DM, *et al.* 2012 Identification and validation of novel Adipokines released from primary human adipocytes. *Molecular and Cellular Proteomics* **11** M111.010504. (<https://doi.org/10.1074/mcp.M111.010504>)
- Li C, Engstrom G, Hedblad B, Calling S, Berglund G & Janzon L 2006 Sex differences in the relationships between BMI, WHR and incidence of cardiovascular disease: a population-based cohort study. *International Journal of Obesity* **30** 1775–1781. (<https://doi.org/10.1038/sj.ijo.0803339>)
- Liu P, Li GL, Wu J, Zhou X, Wang LP, Han WQ, Lv Y & Sun CF 2015 Vaspin promotes 3T3-L1 preadipocyte differentiation. *Experimental Biology and Medicine* **240** 1520–1527. (<https://doi.org/10.1177/1535370214565081>)
- Liu SW, Li X, Wu YR, Duan RX, Zhang JX, Dui F, Zhang Q, Li YB & Li NS 2017 Effects of vaspin on pancreatic beta cell secretion via PI3K/Akt and NF-kappa B signaling pathways. *PLoS One* **12** e0189722. (<https://doi.org/10.1371/journal.pone.0189722>)
- Liu S, Duan R, Wu Y, Du F, Zhang J, Li X, Guo S, Wang M, Zhang Q, Li Y, *et al.* 2018 Effects of vaspin on insulin resistance in rats and underlying mechanisms. *Scientific Reports* **8** 13542. (<https://doi.org/10.1038/s41598-018-31923-3>)

- Maria Z, Campolo AR & Lacombe VA 2015 Diabetes alters the expression and translocation of the insulin-sensitive glucose Transporters 4 and 8 in the atria. *PLoS One* **10** e0146033. (<https://doi.org/10.1371/journal.pone.0146033>)
- Matsuo K, Gray MJ, Yang DY, Srivastava SA, Tripathi PB, Sonoda LA, Yoo EJ, Dubeau L, Lee AS & Lin YG 2013 The endoplasmic reticulum stress marker, glucose-regulated protein-78 (GRP78) in visceral adipocytes predicts endometrial cancer progression and patient survival. *Gynecologic Oncology* **128** 552–559. (<https://doi.org/10.1016/j.ygyno.2012.11.024>)
- McGee SL, van Denderen BJ, Howlett KF, Mollica J, Schertzer JD, Kemp BE & Hargreaves M 2008 AMP-activated protein kinase regulates GLUT4 transcription by phosphorylating histone deacetylase 5. *Diabetes* **57** 860–867. (<https://doi.org/10.2337/db07-0843>)
- Montell E, Turini M, Marotta M, Roberts M, Noe V, Ciudad CJ, Mace K & Gomez-Foix AM 2001 DAG accumulation from saturated fatty acids desensitizes insulin stimulation of glucose uptake in muscle cells. *American Journal of Physiology. Endocrinology and Metabolism* **280** E229–E237. (<https://doi.org/10.1152/ajpendo.2001.280.2.E229>)
- Montessuit C, Rosenblatt-Velin N, Papageorgiou I, Campos L, Pellieux C, Palma T & Lerch R 2004 Regulation of glucose transporter expression in cardiac myocytes: p38 MAPK is a strong inducer of GLUT4. *Cardiovascular Research* **64** 94–104. (<https://doi.org/10.1016/j.cardiores.2004.06.005>)
- Nakatsuka A, Wada J, Iseda I, Teshigawara S, Higashio K, Murakami K, Kanzaki M, Inoue K, Terami T, Katayama A, *et al.* 2012 Vaspin is an adipokine ameliorating ER stress in obesity as a ligand for cell-surface GRP78/MJ-1 complex. *Diabetes* **61** 2823–2832. (<https://doi.org/10.2337/db12-0232>)
- Nicholson T, Church C, Baker DJ & Jones SW 2018 The role of adipokines in skeletal muscle inflammation and insulin sensitivity. *Journal of Inflammation* **15** 9. (<https://doi.org/10.1186/s12950-018-0185-8>)
- Niu W, Huang C, Nawaz Z, Levy M, Somwar R, Li D, Bilan PJ & Klip A 2003 Maturation of the regulation of GLUT4 activity by p38 MAPK during L6 cell myogenesis. *Journal of Biological Chemistry* **278** 17953–17962. (<https://doi.org/10.1074/jbc.M211136200>)
- O'Leary ME, Wallace GR, Bennett AJ, Tsintzas K & Jones SW 2017 IL-15 promotes human myogenesis and mitigates the detrimental effects of TNF α on myotube development. *Scientific Reports* **7** 12997. (<https://doi.org/10.1038/s41598-017-13479-w>)
- Pellegrinelli V, Rouault C, Rodriguez-Cuenca S, Albert V, Edom-Vovard E, Vidal-Puig A, Clement K, Butler-Browne GS & Lacasa D 2015 Human adipocytes induce inflammation and atrophy in muscle cells during obesity. *Diabetes* **64** 3121–3134. (<https://doi.org/10.2337/db14-0796>)
- Pratley RE, Hagberg JM, Rogus EM & Goldberg AP 1995 Enhanced insulin sensitivity and lower waist-to-hip ratio in master athletes. *American Journal of Physiology* **268** E484–E490. (<https://doi.org/10.1152/ajpendo.1995.268.3.E484>)
- Rosqvist F, Bjermo H, Kullberg J, Johansson L, Michaelsson K, Ahlstrom H, Lind L & Riserus U 2017 Fatty acid composition in serum cholesterol esters and phospholipids is linked to visceral and subcutaneous adipose tissue content in elderly individuals: a cross-sectional study. *Lipids in Health and Disease* **16** 68. (<https://doi.org/10.1186/s12944-017-0445-2>)
- Rossi AP, Watson NL, Newman AB, Harris TB, Kritchevsky SB, Bauer DC, Satterfield S, Goodpaster BH & Zamboni M 2011 Effects of body composition and adipose tissue distribution on respiratory function in elderly men and women: the health, aging, and body composition study. *Journals of Gerontology. Series A, Biological Sciences and Medical Sciences* **66** 801–808. (<https://doi.org/10.1093/gerona/qlr059>)
- Seeger J, Ziegelmeier M, Bachmann A, Lossner U, Kratzsch J, Bluher M, Stumvoll M & Fasshauer M 2008 Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. *Journal of Clinical Endocrinology and Metabolism* **93** 247–251. (<https://doi.org/10.1210/jc.2007-1853>)
- Skurk T, Alberti-Huber C, Herder C & Hauner H 2007 Relationship between adipocyte size and adipokine expression and secretion. *Journal of Clinical Endocrinology and Metabolism* **92** 1023–1033. (<https://doi.org/10.1210/jc.2006-1055>)
- Sun N, Wang H & Wang L 2015 Vaspin alleviates dysfunction of endothelial progenitor cells induced by high glucose via PI3K/Akt/eNOS pathway. *International Journal of Clinical and Experimental Pathology* **8** 482–489.
- Teshigawara S, Wada J, Hida K, Nakatsuka A, Eguchi J, Murakami K, Kanzaki M, Inoue K, Terami T, Katayama A, *et al.* 2012 Serum vaspin concentrations are closely related to insulin resistance, and rs77060950 at SERPINA12 genetically defines distinct group with higher serum levels in Japanese population. *Journal of Clinical Endocrinology and Metabolism* **97** E1202–E1207. (<https://doi.org/10.1210/jc.2011-3297>)
- Thiebaud D, Jacot E, DeFronzo RA, Maeder E, Jequier E & Felber JP 1982 The effect of graded doses of insulin on total glucose uptake, glucose oxidation, and glucose storage in man. *Diabetes* **31** 957–963. (<https://doi.org/10.2337/diacare.31.11.957>)
- Tilg H & Moschen AR 2006 Adipocytokines: mediators linking adipose tissue, inflammation and immunity. *Nature Reviews Immunology* **6** 772–783. (<https://doi.org/10.1038/nri1937>)
- Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL & Ferrante AW Jr 2003 Obesity is associated with macrophage accumulation in adipose tissue. *Journal of Clinical Investigation* **112** 1796–1808. (<https://doi.org/10.1172/JCI19246>)
- Wentworth JM, Naselli G, Brown WA, Doyle L, Phipson B, Smyth GK, Wabitsch M, O'Brien PE & Harrison LC 2010 Pro-inflammatory CD11c+CD206+ adipose tissue macrophages are associated with insulin resistance in human obesity. *Diabetes* **59** 1648–1656. (<https://doi.org/10.2337/db09-0287>)
- White UA & Tchoukalova YD 2014 Sex dimorphism and depot differences in adipose tissue function. *Biochimica et Biophysica Acta* **1842** 377–392. (<https://doi.org/10.1016/j.bbdis.2013.05.006>)
- Yilmaz E 2017 Endoplasmic reticulum stress and obesity. *Advances in Experimental Medicine and Biology* **960** 261–276. (https://doi.org/10.1007/978-3-319-48382-5_11)
- Youn BS, Kloting N, Kratzsch J, Lee N, Park JW, Song ES, Ruschke K, Oberbach A, Fasshauer M, Stumvoll M, *et al.* 2008 Serum vaspin concentrations in human obesity and type 2 diabetes. *Diabetes* **57** 372–377. (<https://doi.org/10.2337/db07-1045>)
- Zeyda M & Stulnig TM 2007 Adipose tissue macrophages. *Immunology Letters* **112** 61–67. (<https://doi.org/10.1016/j.imlet.2007.07.003>)
- Zeyda M, Farmer D, Todoric J, Aszmann O, Speiser M, Gyori G, Zlabinger GJ & Stulnig TM 2007 Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production. *International Journal of Obesity* **31** 1420–1428. (<https://doi.org/10.1038/sj.ijo.0803632>)
- Zeyda M, Huber J, Prager G & Stulnig TM 2011 Inflammation correlates with markers of T-cell subsets including regulatory T cells in adipose tissue from obese patients. *Obesity* **19** 743–748. (<https://doi.org/10.1038/oby.2010.123>)
- Zhang Y, Liu R, Ni M, Gill P & Lee AS 2010 Cell surface relocalization of the endoplasmic reticulum chaperone and unfolded protein response regulator GRP78/BiP. *Journal of Biological Chemistry* **285** 15065–15075. (<https://doi.org/10.1074/jbc.M109.087445>)

Received in final form 28 January 2019

Accepted 5 February 2019

Accepted Preprint published online 5 February 2019